Navigation Links
Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences
Date:5/21/2010

able and Results in Durable Responses, (abstract # 433), Mariele Goebeler, Wurzburg University Hospital, will report updated results from an on-going Phase 1 trial of blinatumomab in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).  Dr. Goebeler will present an update on the experience of patients treated with blinatumomab utilizing a new dosing algorithm on June 12 from 9:00 – 9:15 AM CET.

At the 2010 American Society of Clinical Oncology Annual Meeting, to be held June 4 – 8 in Chicago, Walter Fiedler, Department of Medicine II, University Hospital Hamburg-Eppendorf will report updated results from an ongoing Phase 1 trial of MT110 in patients with advanced solid tumors.  In a poster presentation titled Phase I Safety and Pharmacology Study of the EpCAM/CD3-bispecific BiTE® Antibody MT110 in Patients with Metastatic Colorectal, Gastric or Lung Cancer (abstract # 2573), Dr. Fiedler will present interim findings from this dose escalation study on June 7 from 8:00 AM12:00 PM CST.

Abstracts can be found at www.ehaweb.org and www.asco.org.

About Blinatumomab

Blinatumomab (
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... word boundaryless to describe his vision for GE. ... hierarchical, get-seven-signatures-before-buying-toilet-paper, bureaucratic B.S. that crippled GEs ability ... decisions, and empower people. , ,Economic developers would ... playbook. Why? Because markets are already moving in ...
... three days of June, the first through the third, will ... US, Japan, Germany, France, Italy, Britain, Canada and Russia, have ... missing from the party, and given their importance on the ... meetings are photo opportunities for the heads of state to ...
... Interview with Josh Heling, co-founder, SecurePipe, Inc. ... variety of industries including manufacturing, healthcare, banking, environmental response, ... social engineering, raising money, and ecruiting a CEO. , ... a little about SecurePipe. , , Josh Heling ...
Cached Biology Technology:Are We Headed for a Global Economic Collapse? 2WTN Exclusive Interview with Josh Heling 2WTN Exclusive Interview with Josh Heling 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... FASEB MARC (Minority Access to Research Careers) Program has ... Italiana di Patologia (SIP) XXX National Congress in Salerno, ... meant to promote the entry of underrepresented minority students, ... science community and to encourage the participation of young ...
... St. Jude Children,s Research Hospital investigators adds to evidence that ... brain and visual system, safeguarding the future retina by keeping ... signaling protein capable of disrupting the process. The findings ... system as a key regulator of the Wnt family of ...
... in French . , A team of ... Center for Interdisciplinary Research in Biology, Health, Environment and ... and a researcher at Sainte-Justine University Hospital, and Donna ... and a member of CINBIOSE, recently completed a study ...
Cached Biology News:Scientists show Six3 gene essential for retinal development 2Manganese in drinking water: Study suggests adverse effects on children's intellectual abilities 2Manganese in drinking water: Study suggests adverse effects on children's intellectual abilities 3
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Disrupts biological cells for DNA ... 96 well plates (includes 96 well ... consistent lysis across the entire plate ... wells). Can be used for ...
Request Info...
GBL Antibody...
Biology Products: